JP2024520674A5 - - Google Patents

Info

Publication number
JP2024520674A5
JP2024520674A5 JP2023574472A JP2023574472A JP2024520674A5 JP 2024520674 A5 JP2024520674 A5 JP 2024520674A5 JP 2023574472 A JP2023574472 A JP 2023574472A JP 2023574472 A JP2023574472 A JP 2023574472A JP 2024520674 A5 JP2024520674 A5 JP 2024520674A5
Authority
JP
Japan
Prior art keywords
group
ch2ch2o
iii
pharmaceutically acceptable
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520674A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/096690 external-priority patent/WO2022253284A1/zh
Publication of JP2024520674A publication Critical patent/JP2024520674A/ja
Publication of JP2024520674A5 publication Critical patent/JP2024520674A5/ja
Pending legal-status Critical Current

Links

JP2023574472A 2021-06-02 2022-06-01 薬物コンジュゲート及びその使用 Pending JP2024520674A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN2021098024 2021-06-02
CNPCT/CN2021/098024 2021-06-02
CN202110651300 2021-06-10
CN202110651300.6 2021-06-10
CN202111198590.X 2021-10-14
CN202111198590 2021-10-14
CN202111595515.7 2021-12-23
CN202111595515 2021-12-23
CN202111602429 2021-12-24
CN202111602429.4 2021-12-24
PCT/CN2022/096690 WO2022253284A1 (zh) 2021-06-02 2022-06-01 药物偶联物及其用途

Publications (2)

Publication Number Publication Date
JP2024520674A JP2024520674A (ja) 2024-05-24
JP2024520674A5 true JP2024520674A5 (cg-RX-API-DMAC7.html) 2025-06-06

Family

ID=84240734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574472A Pending JP2024520674A (ja) 2021-06-02 2022-06-01 薬物コンジュゲート及びその使用

Country Status (5)

Country Link
US (1) US20240269315A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349371A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520674A (cg-RX-API-DMAC7.html)
CN (2) CN117295524A (cg-RX-API-DMAC7.html)
WO (1) WO2022253284A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4273167A4 (en) * 2020-12-30 2025-03-26 Bio-Thera Solutions, Ltd. ANTI-CLDN18.2 ANTIBODIES AND PRODUCTION METHOD AND USE THEREOF
US20250262316A1 (en) * 2021-10-14 2025-08-21 Bio-Thera Solutions, Ltd. Antibody-drug conjugate and application thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN116333135A (zh) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
EP4509141A4 (en) * 2022-04-12 2026-08-19 Bio Thera Solutions Ltd TREATMENT METHOD FOR A HER2-POSITIVE SOLID TUMOR
WO2023232080A1 (zh) * 2022-06-01 2023-12-07 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其抗体药物偶联物和用途
CN119421724A (zh) * 2022-06-27 2025-02-11 百奥泰生物制药股份有限公司 治疗实体瘤的方法
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
EP4650355A1 (en) * 2023-01-09 2025-11-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Preparation method for nitrogen-containing fused ring compound
KR20250152646A (ko) * 2023-03-01 2025-10-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인데노[1,2-b]퀴놀린-10,13-디온 유도체의 제조 방법
WO2025002310A1 (zh) * 2023-06-29 2025-01-02 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
CN121772942A (zh) * 2023-08-11 2026-03-31 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物在治疗疾病中的应用
AU2024369355A1 (en) * 2023-10-23 2026-05-07 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Camptothecin drug conjugate, and preparation method therefor and use thereof
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025190255A1 (zh) * 2024-03-12 2025-09-18 百奥泰生物制药股份有限公司 治疗宫颈癌、胸腺肿瘤或激素受体阳性和her2阴性乳腺癌的方法
WO2025190251A1 (zh) * 2024-03-12 2025-09-18 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途
WO2025190318A1 (zh) * 2024-03-13 2025-09-18 百奥泰生物制药股份有限公司 抗her2抗体药物偶联物和her二聚化抑制剂联合治疗实体瘤
CN120837674A (zh) * 2024-04-28 2025-10-28 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物治疗肿瘤的方法
CN120919340A (zh) * 2024-05-09 2025-11-11 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用
CN121015903A (zh) * 2024-05-27 2025-11-28 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和vegf-a抑制剂联合治疗肿瘤的用途
CN121015902A (zh) * 2024-05-27 2025-11-28 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
WO2026002234A1 (zh) * 2024-06-29 2026-01-02 百奥泰生物制药股份有限公司 药物偶联物及其制备方法和用途
CN121606577A (zh) * 2024-08-27 2026-03-06 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用
WO2026108920A1 (zh) * 2024-11-20 2026-05-28 江苏恒瑞医药股份有限公司 配体-药物偶联物及其医药用途
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235269C (en) 1995-10-19 2006-09-19 Bristol-Myers Squibb Company Monoclonal antibody br110 and uses thereof
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Trop-2抗体
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
PT3057585T (pt) * 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
MY199595A (en) * 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
US20210093733A1 (en) * 2016-11-21 2021-04-01 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CN111936169A (zh) * 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
WO2019243825A1 (en) * 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
CN110862454B (zh) 2018-08-27 2022-12-30 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
CN110903395A (zh) 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 抗体、偶联物及其制备方法和用途
JP7401538B2 (ja) 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗cldn18.2抗体およびその使用
EP3876998A1 (en) * 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
CA3140063A1 (en) * 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
CA3085001C (en) * 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
JP7641967B2 (ja) 2019-12-06 2025-03-07 ソティオ バイオテック エイ.エス. ヒト化cldn18.2抗体
US20230101735A1 (en) 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
US20230312704A1 (en) 2020-02-10 2023-10-05 Shanghai Escugen Biotechnology Co., Ltd. Cldn18.2 antibody and use thereof
WO2021238831A1 (en) 2020-05-25 2021-12-02 Mabspace Biosciences (Suzhou) Co., Limited Anti-cldn18.2 antibodies and diagnostic uses thereof
CN116589587A (zh) 2020-06-22 2023-08-15 四川百利药业有限责任公司 一种抗trop2抗体

Similar Documents

Publication Publication Date Title
JP2024547111A5 (cg-RX-API-DMAC7.html)
AU2018267660B2 (en) Compounds and methods for the treatment of TROP2 positive diseases
CN103269712B (zh) 包含新型安丝菌素衍生物的细胞毒性剂
RU2523419C2 (ru) Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений
US8841425B2 (en) Cytotoxic agents comprising new maytansinoids
CN103333246B (zh) 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
CN103288957B (zh) 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
HRP20130953T1 (hr) Pirolobenzodiazepini i njihovi konjugati
US20250249114A1 (en) Method for treating her2-positive solid tumor
CN1816356A (zh) 药物缀合物组合物
CA2525130A1 (en) Improved cytotoxic agents comprising new maytansinoids
CN102731611A (zh) 细霉素衍生物
CN119421724A (zh) 治疗实体瘤的方法
Hamann Monoclonal antibody–drug conjugates
WO2025190255A1 (zh) 治疗宫颈癌、胸腺肿瘤或激素受体阳性和her2阴性乳腺癌的方法
CN120837674A (zh) 抗Nectin-4抗体药物偶联物治疗肿瘤的方法
CN119454999A (zh) 抗FRα抗体药物偶联物在治疗疾病中的应用
CN119899238A (zh) 稠环化合物及其制备方法和用途
HK1092730A (en) Drug conjugate composition